Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
An analysis of BioCentury’s Distillery captures trends and licensing opportunities from preclinical studies published in 2020.
Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as well as new indications and technologies for targets already flagged by industry.
BioCentury’s Distillery, a curated collection of top translational studies in the scientific literature, provides summaries of preclinical papers showing innovative interventions with disease-modifying effects.
An analysis cross-referencing 164 papers captured by the Distillery in 2020 to the competitive landscape reflected in BioCentury’s BCIQ database identified 78 studies featuring targets not represented in any disclosed, active company programs.
These white space targets include new entrants into hot target categories such as E3 ligases, which are a big focus for the next-generation of targeted protein degraders.
And while the explosive boom in COVID-19 studies dominated the headlines, researchers also